PhRMA campaign touts Part D positives

Share this article:
PhRMA campaign touts Part D positives
PhRMA campaign touts Part D positives
PhRMA launched a national TV ad campaign aimed in part at dissuading congressional Democrats from tampering with the Medicare Part D prescription drug benefit to allow the government to negotiate drug prices.

The ad celebrates the successes of Medicare Part D, and asks viewers to call 202-224-3121 and “tell Congress we need quality affordable healthcare coverage for every American.”

“All across America, over 26 million seniors have signed up for Medicare drug coverage, choosing a private plan that fits their needs, and saving an average of $1,200.00 a year on their prescription medicine,” says the ad's narrator. “And with competition holding down costs, taxpayers are saving billions. The Medicare benefit is working, and seniors are happy.”

According to a PhRMA release, the campaign touts “the importance and success of free-market initiatives such as [Medicare Part D].” The “free-market” elements of Medicare Part D – in particular, a policy provision barring Medicare from negotiating drug prices with manufacturers – have been challenged anew by congressional Democrats.

Two bills introduced in Congress last January, one in the House (H.R.684) and one in Senate (S.330), by Rep. Robert Berry (D-AR) and Sen. Richard Durbin (D-IL), respectively, would empower government officials to “negotiate with pharmaceutical manufactures with respect to the purchase price of covered part D drugs.”
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.